miR-34a is a tumor suppressor in zebrafish and its expression levels impact metabolism, hematopoiesis and DNA damage
PLOS Genetics · 2024
DOI: 10.1371/journal.pgen.1011290 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, 2024. Verfasst von Sergey V Prykhozhij und 12 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Eastern Ontario (CHEO) Research Institute and University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: DNA Damage, Hematopoiesis, MicroRNAs, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Ontario Graduate Scholarship, CIHR Canada Graduate Scholarship – Doctoral.
Abstract (Originalsprache)
Li-Fraumeni syndrome is caused by inherited TP53 tumor suppressor gene mutations. MicroRNA miR-34a is a p53 target and modifier gene. Interestingly, miR-34 triple-null mice exhibit normal p53 responses and no overt cancer development, but the lack of miR-34 promotes tumorigenesis in cancer-susceptible backgrounds. miR-34 genes are highly conserved and syntenic between zebrafish and humans. Zebrafish miR-34a and miR-34b / c have similar expression timing in development, but miR-34a is more abundant. DNA damage by camptothecin led to p53-dependent induction of miR-34 genes, while miR-34a mutants were adult-viable and had normal DNA damage-induced apoptosis. Nevertheless, miR-34a -/- compound mutants with a gain-of-function tp53 R217H/ R217H or tp53-/- mutants were more cancer-prone than tp53 mutants alone, confirming the tumor-suppressive function of miR-34a . Through transcriptomic comparisons at 28 hours post-fertilization (hpf), we characterized DNA damage-induced transcription, and at 8, 28 and 72 hpf we determined potential miR-34a-regulated genes. At 72 hpf, loss of miR- 34a enhanced erythrocyte levels and up-regulated myb -positive hematopoietic stem cells. Overexpression of miR-34a suppressed its reporter mRNA, but not p53 target induction, and sensitized injected embryos to camptothecin but not to γ-irradiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Children's Hospital of Eastern Ontario (CHEO) Research Institute and University of Ottawa, Ottawa, Ontario, Canada.
- Dalhousie University Medical School, Halifax, Nova Scotia, Canada.
- Atlantic Cancer Research Institute, Pavillon Hôtel-Dieu, 35 Providence Street, Moncton, NB, Canada.
- HHS McMaster University Medical Centre, Division of Medical Microbiology, Hamilton, Ontario, Canada.
- Atlantic Cancer Research Institute, Pavillon Hôtel-Dieu, Moncton, New Brunswick, Canada.
- Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
ORCID-Profile: Sergey V Prykhozhij, Jason N Berman
Förderung
- Canadian Institutes of Health Research
- Ontario Graduate Scholarship
- CIHR Canada Graduate Scholarship – Doctoral
Zitieren
APA
Prykhozhij, S. V., Ban, K., Brown, Z. L., Kobar, K., Wajnberg, G., Fuller, C., Chacko, S., Lacroix, J., Crapoulet, N., Midgen, C., Shlien, A., Malkin, D., & Berman, J. N. (2024). miR-34a is a tumor suppressor in zebrafish and its expression levels impact metabolism, hematopoiesis and DNA damage. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1011290
Vancouver
Prykhozhij SV, Ban K, Brown ZL, Kobar K, Wajnberg G, Fuller C, et al. miR-34a is a tumor suppressor in zebrafish and its expression levels impact metabolism, hematopoiesis and DNA damage. PLOS Genetics. 2024. doi:10.1371/journal.pgen.1011290
BibTeX
@article{Prykhozhij2024,
author = {Prykhozhij, Sergey V and Ban, Kevin and Brown, Zane L and Kobar, Kim and Wajnberg, Gabriel and Fuller, Charlotte and Chacko, Simi and Lacroix, Jacynthe and Crapoulet, Nicolas and Midgen, Craig and Shlien, Adam and Malkin, David and Berman, Jason N},
title = {miR-34a is a tumor suppressor in zebrafish and its expression levels impact metabolism, hematopoiesis and DNA damage},
journal = {PLOS Genetics},
year = {2024},
doi = {10.1371/journal.pgen.1011290}
}
EUVIMED